Last update July 16, 2022

Canakinumab

Compatible

Safe substance and/or breastfeeding is the best option.

Canakinumab es un anticuerpo monoclonal humano recombinante contra la interleucina-1β que se utiliza para el tratamiento de la artritis gotosa, la artritis juvenil y los síndromes de fiebre periódica. Administración subcutánea cada 4 a 12 semanas.

Its very high molecular weight explain the null or negligible passage to breast milk observed. (Weber 2022, Bosshard 2021)

No clinical problems or a higher rate of infections and no problems with routine vaccinations have been observed in infants of mothers receiving this drug. (Weber 2022, İlgen 2022, Bosshard 2021, Youngstein 2017)

Due to its protein nature, it is inactivated in the gastrointestinal tract, not being absorbed (practically nil oral bioavailability), which hinders or prevents the passage into plasma of the infant from ingested breast milk (Lactmed), except in premature infants and during the immediate neonatal period, in which there may be greater intestinal absorption.

Alternatives

We do not have alternatives for Canakinumab since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Canakinumab in other languages or writings:

  • Канакинумаб (Cyrillic)
  • カナキヌマブ (Japanese)
  • ACZ-885 ; ACZ885 (Experimental code/s)
  • Immunoglobulin G1, anti-(human interleukin-1 beta (IL-1β)) human monoclonal ACZ885; (1Glu>Glp)-γ1 heavy chain (221-214′)-disulfide with kappa light chain, dimer (227-227″:230-230″)-bisdisulfide
    CAS: 402710-25-2 (heavy chain); 402710-27-4 (light chain); 914613-48-2 (canakinumab) (Chemical name)
  • C6452H9958N1722O2010S42 (Molecular formula)
  • L04AC08 (ATC Code/s)

Groups

Canakinumab belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Canakinumab in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 145.200 daltons
VD 0.09 l/Kg
624 hours
Theoretical Dose 0 - 0.0035 mg/Kg/d
Relative Dose < 0.08 %

References

  1. Weber E, Millet A, Beghin D, Viel S, Guitton J, Gerfaud-Valentin M, Sève P, Jamilloux Y. Safety of canakinumab during pregnancy: seven new cases. Rheumatology (Oxford). 2022 Mar 24. pii: keac177. Consulted on July 16, 2022 Abstract
  2. İlgen U, Eyüpoğlu Ş, Yayla ME, Küçükşahin O. Fetal exposure to canakinumab: a report of three pregnancies. Clin Rheumatol. 2022 Apr;41(4):1261-1263. Consulted on July 16, 2022 Abstract
  3. Stratigakis A, Paty D, Zou P, Zhao Z, Li Y, Zhang T. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207 Full text (link to original source) Full text (in our servers)
  4. Bosshard N, Zbinden A, Eriksson KK, Förger F. Rituximab and Canakinumab Use During Lactation: No Detectable Serum Levels in Breastfed Infants. Rheumatol Ther. 2021 Jun;8(2):1043-1048. Abstract Full text (link to original source)
  5. Novartis. Canakinumab. Drug Summary. 2021 Full text (in our servers)
  6. Novartis. Canakinumab. Ficha técnica. 2019 Full text (in our servers)
  7. Youngstein T, Hoffmann P, Gül A, Lane T, Williams R, Rowczenio DM, Ozdogan H, Ugurlu S, Ryan J, Harty L, Riminton S, Headley AP, Roesler J, Blank N, Kuemmerle-Deschner JB, Simon A, Woolf AS, Hawkins PN, Lachmann HJ. International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology (Oxford). 2017 Dec 1;56(12):2102-2108. Abstract Full text (link to original source)

Total visits

948

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM